Episode Details
Back to EpisodesSGEM#525: You’ve got the Flu, I’ve got the Remedy?
Published 2 weeks ago
Description
Reference: Huang Y-N, et al. Early Antiviral Therapy in Pediatric Outpatients and Risk of Influenza-Related Hospitalization. Pediatrics. 2026
Date: September 29, 2026
Dr. Gabrielle Jasmine
Guest Skeptic: Dr. Gabrielle Jasmine is a pediatric emergency medicine fellow at Children’s National Hospital in Washington DC. Her research interests include health equity, social determinants of health, and medical education.
Case: A previously healthy 7-year-old boy presents to the emergency department (ED) with fever, cough, rhinorrhea, and decreased energy. His parents tell you that these symptoms have been going on for the past day and a half. Influenza A testing is performed and is positive. On your exam, the boy is mildly tachycardic with the fever but otherwise well appearing. Oxygen saturation is normal. He is not in any respiratory distress, and he is drinking an apple juice.
The parent asks you, “I remember feeling really miserable when I got the flu, and I heard that there are some kids who can get really sick from it. Are there any particular medications that can treat the virus?”
Background:
Influenza is common in children and, for many, is a self-limited illness. The clinical spectrum can range from a nonspecific febrile illness with upper respiratory symptoms to bronchiolitis, croup, gastrointestinal symptoms, and other relatively uncomplicated presentations. However, influenza can also cause serious complications, including pneumonia, myocarditis, myositis, rhabdomyolysis, secondary bacterial infections, and neurologic disease. The 2026–2027 American Academy of Pediatrics (AAP) technical report notes that neurologic complications occur in approximately 8% to 11% of children hospitalized with influenza and can include seizures, encephalitis, and influenza-associated encephalopathy or encephalitis (IAE).
One particularly devastating form is acute necrotizing encephalopathy (ANE), characterized by rapid neurologic deterioration and characteristic bilateral brain lesions, often involving the thalami. Although uncommon, the morbidity and mortality remind us that the clinically important question about influenza treatment is not simply whether we can make a child feel better a little sooner, but whether we can prevent progression to serious disease.
Antiviral medications are recommended by multiple professional organizations for children at higher risk for complications, including the CDC. Treatment can also be considered for otherwise healthy children when started early in the course of illness.
The most familiar of these medications is oseltamivir, or Tamiflu, which is the AAP’s antiviral of choice. It is an oral neuraminidase inhibitor that prevents newly formed influenza virions from being released from infected cells. Randomized trials in children suggest that oseltamivir may shorten symptoms by roughly a day and may decrease the risk of acute otitis media. What has been far less clear is whether it prevents the outcomes that matter even more to patients and clinicians, such as hospitalization, critical illness, or death.
Tamiflu also has a somewhat notorious and controversial history. Much of the original phase III evidence supporting oseltamivir was not initially published, leading Cochrane investigators and The BMJ to spend years seeking access to the complete clinical study reports from the manufacturer, Roche. When the fuller dataset was eventually examined, the benefits appeared more modest and adverse effects such as nausea and vomiting became more apparent. The saga has become a classic example of publication bias, selective reporting, and the importance of data transparency.
The controversy has not gone away. Recently, SGEM#518 reviewed a recent randomized trial of critically ill, predominantly adult patients with influenza requiring respiratory or cardiovascular organ support. In that study, oseltamivir not only did not improve survival, but it also showed a concerning signal of increased mortality.